Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.692
-0.004 (-0.60%)
Nov 21, 2024, 11:34 AM EST - Market open
Gossamer Bio Employees
Gossamer Bio had 135 employees as of December 31, 2023. The number of employees decreased by 43 or -24.16% compared to the previous year.
Employees
135
Change (1Y)
-43
Growth (1Y)
-24.16%
Revenue / Employee
$780,163
Profits / Employee
-$530,719
Market Cap
156.62M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
The Joint | 794 |
Tenaya Therapeutics | 140 |
Alpha Tau Medical | 121 |
MediWound | 100 |
Fulcrum Therapeutics | 76 |
Lineage Cell Therapeutics | 75 |
Atossa Therapeutics | 12 |
Greenwich LifeSciences | 7 |
GOSS News
- 9 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss - Seeking Alpha
- 3 months ago - Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024 - Business Wire
- 3 months ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire
- 3 months ago - Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says - Benzinga
- 6 months ago - Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference - Business Wire